GLP-1 receptor

Class

GLP-1 receptor agonist

The glucagon-like peptide-1 (GLP-1) receptor is a G protein-coupled receptor expressed on pancreatic beta cells, in the central nervous system, and in the gastrointestinal tract. Its natural ligand, GLP-1, is an incretin hormone released from the gut after eating, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and acts on appetite-regulating centers in the brain to promote satiety. Because native GLP-1 is degraded within minutes by the enzyme dipeptidyl peptidase-4, therapeutic strategies use synthetic peptides, engineered proteins, or small molecules that activate the receptor with greater metabolic stability and prolonged duration of action. Agonism of this receptor addresses two intertwined disease processes: impaired glucose regulation in type 2 diabetes and excess body weight, since the same receptor pathway that improves insulin release and lowers blood glucose also reduces caloric intake. The breadth of chemical modalities pursued for this target, spanning injectable peptides, longer-acting fusion proteins, and increasingly oral small molecules, reflects efforts to improve convenience, dosing frequency, and manufacturing while achieving comparable receptor activation. Combination approaches pairing GLP-1 agonism with other hormonal pathways aim to extend metabolic benefit beyond what receptor activation alone provides.